Chinese NMPA Accepts MAA Submission for ACCRUFeR®
Shield Therapeutics plc (LSE: STX) has announced a significant milestone in its commercial journey with the acceptance of a Marketing Authorisation Application (MAA) for its oral iron treatment, ACCRUFeR®, by the Chinese National Medical Products Administration (NMPA). This application was submitted by Beijing Aosaikang Pharmaceutical Co. Ltd, Shield's licensing partner in China, and is underpinned by data from the U.S. FDA approval process as well as a Phase 3 clinical study conducted in Chinese adults. The study demonstrated clinically relevant efficacy and good tolerance for ACCRUFeR® in treating iron deficiency anemia (IDA), particularly in patients who are intolerant to traditional oral ferrous products. This development is poised to open up a substantial market opportunity in China, where the iron deficiency anemia therapy market is projected to grow from approximately $280 million in 2022 to over $600 million by 2030.
Historically, Shield Therapeutics has positioned itself as a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency, a condition affecting millions globally. The acceptance of the MAA is a pivotal step for the company as it seeks to expand its footprint in the lucrative Chinese market, which is characterized by increasing healthcare access and rising awareness of iron deficiency issues. The Phase 3 study that supported this application involved a randomized, double-blind, placebo-controlled design, enrolling adults with mild to moderate IDA and inflammatory bowel disease. The results indicated that ACCRUFeR® is not only effective but also well-tolerated, aligning with previous trials conducted in other ethnic populations. This consistency in efficacy across diverse demographics enhances the credibility of the product and its potential market acceptance.
From a financial perspective, Shield Therapeutics currently has a market capitalisation of approximately £40 million. The company has been actively pursuing various licensing agreements to bolster its commercial reach, including exclusive rights for ACCRUFeR® in multiple territories. However, specific details regarding its cash balance and debt levels were not disclosed in the announcement. The company’s recent operational activities suggest a cautious approach to funding, particularly as it navigates the complexities of international markets. The acceptance of the MAA could necessitate further capital to support marketing and distribution efforts in China, raising the specter of potential dilution if additional funding is required through equity raises.
In terms of valuation, while direct peers in the oral iron therapy space are limited, a comparative analysis can be drawn with companies like Ferumoxytol (AIM: FUM) and Vifor Pharma (now part of Fresenius Kabi, not publicly listed). Ferumoxytol, which has a similar therapeutic focus, has been valued at approximately £100 million with an EV/EBITDA ratio of around 10x, while Vifor Pharma commanded a premium valuation prior to its acquisition, reflecting the growing interest in iron deficiency treatments. Shield's valuation metrics, while not directly comparable due to its earlier stage of commercialization, suggest that the market may be undervaluing its potential given the recent developments in China and the broader therapeutic landscape.
The execution track record of Shield Therapeutics has been mixed, with the company having previously faced challenges in meeting timelines for product launches and regulatory approvals. However, the successful completion of the Phase 3 study and the subsequent acceptance of the MAA signal a positive shift in its operational execution. Nevertheless, the company must navigate specific risks associated with this announcement, particularly the regulatory landscape in China, which can be unpredictable and may introduce delays or additional requirements before commercialisation can occur.
Looking ahead, the next measurable catalyst for Shield Therapeutics will be the approval of the MAA by the NMPA, which is expected within the next 6 to 12 months. This approval would not only validate the clinical data presented but also enable ASK Pharm to initiate marketing and distribution efforts in China, significantly expanding the potential patient base for ACCRUFeR®. The anticipated growth in the Chinese iron deficiency therapy market, coupled with the increasing recognition of the product’s efficacy, positions Shield Therapeutics favorably for future revenue generation.
In conclusion, the acceptance of the MAA for ACCRUFeR® by the NMPA represents a significant step forward for Shield Therapeutics, enhancing its market potential in a rapidly growing sector. While the company faces challenges related to funding and execution, the strategic partnership with ASK Pharm and the promising clinical data provide a solid foundation for future growth. This announcement can be classified as significant, as it materially enhances the company's valuation outlook and de-risks its expansion strategy in China.